ARTICLE | Top Story

SGP, Bayer cross-marketing deal

September 13, 2004 7:00 AM UTC

Schering-Plough (SGP) acquired exclusive rights to market, sell and distribute in the U.S. and Puerto Rico certain primary healthcare products from Bayer Healthcare, a unit of Bayer (FSE:BAYG; BAY). The products include antibiotics Avelox moxifloxacin and Cipro ciprofloxacin, cardiovascular product Adalat nifedipine, and erectile dysfunction drug Levitra vardenafil, which BAYG co-promotes with GlaxoSmithKline (LSE:GSK; GSK).

In Japan, BAYG received rights to co-market SGP's cholesterol-lowering agent Zetia ezetimibe, which is under review in that country. BAYG also will help promote certain SGP oncology products in the U.S. and Europe. ...